- Home
- PLL vs ACRV Comparison
PLL vs ACRV Comparison
Compare PLL & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLL
- ACRV
- Stock Information
- Founded
- PLL 2016
- ACRV 2018
- Country
- PLL United States
- ACRV United States
- Employees
- PLL N/A
- ACRV N/A
- Industry
- PLL Other Metals and Minerals
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- PLL Basic Materials
- ACRV Health Care
- Exchange
- PLL Nasdaq
- ACRV Nasdaq
- Market Cap
- PLL 195.1M
- ACRV 170.3M
- IPO Year
- PLL 2017
- ACRV 2022
- Fundamental
- Price
- PLL $9.08
- ACRV $5.78
- Analyst Decision
- PLL Buy
- ACRV Strong Buy
- Analyst Count
- PLL 9
- ACRV 5
- Target Price
- PLL $22.04
- ACRV $22.40
- AVG Volume (30 Days)
- PLL 391.4K
- ACRV 52.8K
- Earning Date
- PLL 02-20-2025
- ACRV 11-13-2024
- Dividend Yield
- PLL N/A
- ACRV N/A
- EPS Growth
- PLL N/A
- ACRV N/A
- EPS
- PLL N/A
- ACRV N/A
- Revenue
- PLL $46,981,000.00
- ACRV N/A
- Revenue This Year
- PLL $126.75
- ACRV N/A
- Revenue Next Year
- PLL $35.26
- ACRV N/A
- P/E Ratio
- PLL N/A
- ACRV N/A
- Revenue Growth
- PLL N/A
- ACRV N/A
- 52 Week Low
- PLL $6.57
- ACRV $3.19
- 52 Week High
- PLL $18.72
- ACRV $11.90
- Technical
- Relative Strength Index (RSI)
- PLL 41.80
- ACRV 43.36
- Support Level
- PLL $8.59
- ACRV $5.36
- Resistance Level
- PLL $9.53
- ACRV $6.00
- Average True Range (ATR)
- PLL 0.54
- ACRV 0.54
- MACD
- PLL 0.10
- ACRV -0.02
- Stochastic Oscillator
- PLL 30.23
- ACRV 24.73
About PLL Piedmont Lithium Inc.
Piedmont Lithium Inc, is a U.S. based, development-stage, multi-asset, integrated lithium business in support of a clean energy economy and U.S. and world-wide energy security. Its portfolio of wholly-owned projects includes Carolina Lithium, a proposed fully integrated spodumene ore-to-lithium hydroxide project in Gaston County, North Carolina, and Tennessee Lithium, a proposed merchant lithium hydroxide manufacturing plant in McMinn County, Tennessee.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.